


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on November 12, 2007.

COMMUNICATION
Patent Application
Docket No. G-175US03PCT


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : David Lukton, Ph.D.
Art Unit : 1654
Applicants : Kristen Briggs, Deno Dialynas, John Lucas, Aaron Scalia
Serial No. : 10/510,002
Filed : September 29, 2004
Conf. No. : 7745
For : XCRF Polynucleotides and Polypeptides and Uses Thereof


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

COMMUNICATION

Sir:

Applicants received a Restriction Requirement dated October 12, 2007 in the above-identified patent application. The Disposition of Claims on the Office Action Summary page indicates that claims 16-26 are pending. In addition, page 2 of the Restriction Requirement indicates that claims 1-15 have been cancelled and claim 16-26 added by Applicants' Preliminary Amendment. However, Applicants respectfully assert that claims 1-14 were canceled and claims 15-34 were added in the Preliminary Amendment dated September 29, 2004. The issuance of a new Restriction Requirement is respectfully requested taking into account all the pending claims.

Respectfully submitted,


Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl